Histological subtype AFP HCG Primitive germ cell tumours Dysgerminoma − ± Yolk sac tumour ++ − Embryonal carcinoma ± ± Polyembryona ± + Non-gestational choriocarcinoma − ++ Mixed germ…
Pure stromal tumors Fibroma Cellular fibroma Thecoma Luteinized thecoma associated with sclerosing peritonitis Fibrosarcoma Sclerosing stromal tumor Signet-ring stromal tumor Microcystic stromal tumor Leydig cell tumor Steroid cell tumor Steroid…
Stage I: tumor confined to ovaries IA Tumor limited to 1 ovary, capsule intact, no tumor on surface, negative washings IB Tumor involves both ovaries otherwise like IA IC IC1:…
Fig. 15.1 EOC grade 1 Fig. 15.2 EOC grade 3 Adequate sampling of the tumors should enable to establish whether EOC arises in endometriosis, adenofibromatous endometrioid precursors, or de novo….
© Springer International Publishing Switzerland 2017Eric Pujade-Lauraine, Isabelle Ray-Coquard and Fabrice Lécuru (eds.)Ovarian Cancers10.1007/978-3-319-32110-3_20 20. Small Cell Carcinoma of the Ovary Patricia Pautier1 , Aurélie Auguste2 and Alexandra Leary1, 2 (1) Département de médecine oncologique, Gustave Roussy, Université Paris-Saclay, F-94805,…
Fig. 16.1 (Courtesy of Drs/Treilleux, D Pissaloux and Pr/Ray-Coquard from centre leon berard, Lyon) While the low incidence is a barrier to performing effective clinical trials specific to MOC, international…
Gynecological cancer trial groups represented in European Network of Gynecological Oncological Trial Groups Study group (country) AGO – Austria, Arbeitsgemeinschaft Gynäkologische Onkologie Austria AGO Study Group, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe,…
© Springer International Publishing Switzerland 2017Eric Pujade-Lauraine, Isabelle Ray-Coquard and Fabrice Lécuru (eds.)Ovarian Cancers10.1007/978-3-319-32110-3_14 14. Clear Cell Carcinoma Masashi Takano1 , Satoshi Takakura2 and Keiichi Fujiwara3 (1) Department of Clinical Oncology, National Defense Medical College Hospital, 3-2 Namiki, Tokorozawa Saitama, 359-8513,…
PARP inhibitor Company PARP inhibition Details Olaparib (AZD2281) AstraZeneca PARP 1/2/3 Licensed in EU for maintenance BRCAm; ≥3rd line (FDA) in BRCAm. Phase III trials with tablet formulation – first…
Fig. 11.1 The major T cell-based immunotherapeutic targets and their tumor or antigen-presenting cell ligands. The activation of T cells and their conversion to a cytotoxic phenotype is governed by…
